Sarepta (SRPT) SRP-4053 Data Strengthen Case for Exon Expansion Approach - Baird; Reit. OP, $101 PT
Tweet Send to a Friend
Baird analyst Brian Skorney reiterated an Outperform rating and $101 price target on Sarepta Therapeutics (NASDAQ: SRPT) following positive European ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
